Andrew Cap1, Beverley Hunt. 1. aMedical Corps, US Army, Uniformed Services University, Blood Research Program, US Army Institute of Surgical Research, JBSA-FT Sam Houston, San Antonio, Texas, USA bDepartments of Haematology, Pathology and Lupus Guy's & St Thomas' NHS Foundation Trust, London, UK.
Abstract
PURPOSE OF REVIEW: Mortality from trauma remains a global public health challenge, with most preventable deaths due to bleeding. The recognition of acute traumatic coagulopathy as a distinct clinical entity characterized by early coagulation dysfunction, arising prior to medical intervention, has revolutionized trauma management over the last decade. The aim of this article is to review our current understanding of acute traumatic coagulopathy. RECENT FINDINGS: We focus on recent advances in the mechanistic understanding of acute traumatic coagulopathy, particularly the changes in coagulation factors, physiological anticoagulants, endothelial activation, fibrinolysis and platelet dysfunction. Evolving diagnostic and therapeutic approaches are discussed, including viscoelastic coagulation monitoring and the role of tranexamic acid and blood products. SUMMARY: Emphasis is now placed on early prevention, diagnosis, and aggressive initial treatment of coagulopathy and fibrinolysis with haemostatic blood products and tranexamic acid in addition to red cell units in order to reduce bleeding and improve clinical outcomes.
PURPOSE OF REVIEW: Mortality from trauma remains a global public health challenge, with most preventable deaths due to bleeding. The recognition of acute traumatic coagulopathy as a distinct clinical entity characterized by early coagulation dysfunction, arising prior to medical intervention, has revolutionized trauma management over the last decade. The aim of this article is to review our current understanding of acute traumatic coagulopathy. RECENT FINDINGS: We focus on recent advances in the mechanistic understanding of acute traumatic coagulopathy, particularly the changes in coagulation factors, physiological anticoagulants, endothelial activation, fibrinolysis and platelet dysfunction. Evolving diagnostic and therapeutic approaches are discussed, including viscoelastic coagulation monitoring and the role of tranexamic acid and blood products. SUMMARY: Emphasis is now placed on early prevention, diagnosis, and aggressive initial treatment of coagulopathy and fibrinolysis with haemostatic blood products and tranexamic acid in addition to red cell units in order to reduce bleeding and improve clinical outcomes.
Authors: Jean Wong; Ronald B George; Ciara M Hanley; Chadi Saliba; Doreen A Yee; Angela Jerath Journal: Can J Anaesth Date: 2021-05-15 Impact factor: 5.063
Authors: Shawn Tejiram; Soman Sen; Kathleen S Romanowski; David G Greenhalgh; Tina L Palmieri Journal: J Burn Care Res Date: 2020-05-02 Impact factor: 1.845
Authors: Alexander E St John; Jason C Newton; Erika J Martin; Bassem M Mohammed; Daniel Contaifer; Jessica L Saunders; Gretchen M Brophy; Bruce D Spiess; Kevin R Ward; Donald F Brophy; José A López; Nathan J White Journal: J Thromb Haemost Date: 2019-03-18 Impact factor: 5.824
Authors: Ernest E Moore; Hunter B Moore; Lucy Z Kornblith; Matthew D Neal; Maureane Hoffman; Nicola J Mutch; Herbert Schöchl; Beverley J Hunt; Angela Sauaia Journal: Nat Rev Dis Primers Date: 2021-04-29 Impact factor: 65.038